Our Best of February newsletter hits inboxes tomorrow, and it includes insightful, original editorial you won't want to miss. Join the dialog and subscribe for free at cellandgene.com #celltherapy #genetherapy Erin Harris

#GeneTherapy is a fitting approach for diseases caused by a single gene mutation, like #SMA, because it targets the cause of disease by delivering a fully functioning copy of the gene into motor neuron cells. Here's how it works: asgct.org/education/spin… #CureSMA

A promising CAR-T approach to lupus..... fiercebiotech.com/research/exten… FierceBiotech

#CRISPR optimization designed at UT-Southwestern more efficiently restores dystrophin levels in cells derived from both mice and humans and could improve #GeneTherapy for Duchenne muscular dystrophy #DMD. phys.org/news/2019-03-s…

ARM CEO Janet Lambert kicks off Cell & Gene Investor Day with a global sector financial overview & insights into commercial & clinical progress - slides available here: alliancerm.org/wp-content/upl… #CGDay19

#CGDay19 There will never be one vector that supplants all vectors in #GeneTherapy, but AAV isn’t perfect-Mark Kay, Stanford Univ

We are proud to be a sponsor for the Alliance for Regenerative Medicine (ARM) Cell & Gene Therapy Investor Day meeting! We will also be in attendance, if you'd like to set up a time to meet send us a dm. #GeneTherapy #ARMinvestorday #RegenerativeMedicine #CGDay19 #CTI

Thrilled for patients to hear of #Kymriah CAR #Tcell approval in #Japan 🇯🇵 Truly #global therapy oxfordbiomedica.co.uk/news-media/pre…

#GeneTherapy, #CellTherapy, and #GeneEditing are durable, potentially-curative treatment opportunities for diseases that currently have no viable therapy. Though all three have the same goal, each works to alleviate disease in a differently: youtu.be/aO4-KFEz8NE

SanBio announces SB623, a regenerative #celltherapy for traumatic brain injury, has received SAKIGAKE designation from Japan's MHLW - read more here: ssl4.eir-parts.net/doc/4592/tdnet…

Alan Brooks from @CasebiaTx will be giving an oral presentation on our research around liver targeted insertion with LNP/AAV during #ASGCT19 to highlight our findings to date and the potential to treat #hemophiliaA in the future. Read more at casebia.com/wp-content/upl…

Closing thoughts from our panel on opportunities and challenges in the pricing and reimbursement landscape: it is critical for companies to be transparent, consider early the various issues which may impact pricing, and articulate the value of #ATMPs to patients and payors #Med19

Main themes from our panel on the future of #ATMPs: the importance of patient engagement, going-it alone in manufacturing, the role of big pharma in partnering and facilitating access to emerging markets, and prioritising standardisation #Med19

From the Alliance for Regenerative Medicine (ARM) #Med19 meeting: "As we enter day 2, we reflect on a successful and collaborative first day. Cell and gene therapy stakeholders must continue to look at innovative ways to collaborate to ensure patient access." #immunotherapy #cancer

It's World Immunization Week! Ensure you and your family are vaccinated on time, every time. Check with your health worker to see if your vaccines are up-to-date. Yes, #VaccinesWork! 👉bit.ly/2ICUZMx

.@BMoGenBio Chair: #Genomeediting tech to provide antibody validation, disease therapies, gene transfer & mitochondrial DNA editing #Med19 - in room Gadui 2 or online: bit.ly/2vi0eIR

ARM CEO Janet Lambert on pricing and #reimbursement for #ATMPs. It was great to discuss this and many other important sector issues at #Med19 this week!

(video 1/4) We were delighted to catch up with @bluebirdbio CSO Jeff Walsh at #Med19. Here he describes the transformative nature of cell and gene therapies for patients and their families #ATMP

We are proud to announce that Tmunity and UC San Francisco will collaborate to advance TCR T Cell Therapies for Pediatric Cancers | Business Wire businesswire.com/news/home/2019…

Tmunity signs licensing deal for pediatric brain cancer immunotherapy bizjournals.com/philadelphia/n… via Philadelphia Business Journal